●Burning up TNF toxicity for cancer therapy. Leist, M. & Jäätelä, M. Nature Medicine July (2002) This News and Views article reassesses the use of TNF for cancer therapeutics, following a study that shows that its toxicity can be reduced by a 42°C heat shock.

●Protease degradomics: a new challenge for proteomics. López-Otín, C. & Overall, C. M. Nature Reviews Molecular Cell Biology July (2002)

●Focus issue on organogenesis. Nature Reviews Genetics July (2002) A collection of articles on the development of organs such as the liver, heart and pancreas. Together, they reveal the principles that underlie organogenesis.

●Mechanisms and functions of Eph and ephrin signalling. Kullander, K. & Klein, R. Nature Reviews Molecular Cell Biology July (2002)

●T-cell-receptor gene therapy. Schumacher, T. N. M. Nature Reviews Immunology July (2002)

●Glivec (STI-571, imatinib), a rationally developed targeted anticancer drug. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Nature Reviews Drug Discovery July (2002)

●Efp: a ring of independence? Nalepa, G. & Harper, J. W. Nature Medicine July (2002) Breast cancer can become oestrogen independent as the disease progresses. This News and Views article discusses the role that Efp — a ubiquitin ligase (E3) — plays in this transition.

●CTLA-4: new insights into its biological function and use in tumor immunotherapy. Allison, J. Nature Immunology July (2002) The costimulatory molecule CTLA-4 is involved in determining the response to T-cell-receptor stimulation. This review describes its functions, and the potential for its modulation as a strategy for the immunotherapy of cancer.

●Lucky draw in the gene raffle. Pollock, P. M. & Meltzer, P. S. Nature 27 June (2002) This News and Views article discusses the first success of the Cancer Genome Project: the discovery that BRAF is an oncogene in human cancer.